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Affect Treatment Choice and Outcome?
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OBJECTIVE: Age is a known risk factor for breast cancer behaviour. We studied the relationship of age
with clinical characteristics, tumour pathology, therapeutic options and outcome in an affluent Asian
population.
METHODS: From 2003 to 2008, data on newly diagnosed breast carcinoma patients under the care of the
multidisciplinary breast cancer team based at a private hospital in Hong Kong were collected prospectively.
Patients were divided into three groups: age < 40 years (group I), 41–69 years (group II), and ≥ 70 years
(group III). 
RESULTS: There were 2,079 patients: 334 in group I, 1,538 in group II and 148 in group III. The clinical
presentation and tumour stages were similar. Younger patients had higher tumour grading (p = 0.000)
and more lymphovascular permeation (p = 0.011). For older patients, combination therapy was employed
less frequently (p < 0.0005), and more radical resection with less reconstructive procedures were performed
(p = 0.000). The 3-year disease-free survival was 97.8% and there was no difference between the three
groups.
CONCLUSION: Although breast cancer in younger Chinese patients was more aggressive pathologi-
cally, the differences between clinical presentation, tumour staging and survival were similar. Treatment
strategies should follow the clinical condition of the patient rather than age alone. [Asian J Surg 2010;
33(2):97–102]
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Introduction
Breast carcinoma is the most common cancer among
women worldwide, and comprises more than 20% of all
female cancers.1 It is more common in affluent countries,
especially developed western countries.2 Although the
incidence of breast cancer in Asians is much lower than in
Caucasians,3 it is the most frequently occurring cancer in
women in Hong Kong and had the third highest mortality
rate of all female cancers in Hong Kong in 2006.4
The incidence of breast cancer is also increasing glob-
ally2,4 and this has prompted multiple studies to investigate
the risk factors that might have contributed to this surge.
These studies also have tried to identify prognostic factors
for overall survival.5–8 The possible risk factors so far iden-
tified are age; tumour stage (TNM staging), especially
nodal status, hormonal status and hormonal receptor sta-
tus; and histological grade of the tumour (Scarff, Bloom
and Richardson grading).
Hong Kong is an Asian city but has a westernized life
style, especially in the younger population. Thus risk fac-
tors and prognosis of breast cancer in Hong Kong might
be distinct from those in other Asian regions. The present
prospective study explored these factors and the acceptance
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of different therapeutic options among different age
groups in an affluent population in Hong Kong.
Patients and methods
Between 2003 and 2008, all patients with newly diagnosed
breast carcinoma managed under the care of the Multi-
disciplinary Breast Cancer Group based at the Hong Kong
Sanatorium & Hospital were included in the study. The
patient data were collected prospectively and these data
formed the database.
The information recorded for all patients included
their age, past medical health, family history of breast
cancer, mode of first detection, clinical examination find-
ings, and the investigation that led to confirmation of
diagnosis. Breast cancer was staged with the TNM system
(American Joint Committee on Cancer, version 6). The
surgical treatment carried out, the pathological findings
of the tumour, such as tumour size, grade and presence of
lymphovascular permeation, and nodal status were also
recorded. In addition to these the hormonal receptor 
status, Ki67 proliferative index, and human epidermal
growth factor receptor 2 status (HER2) of specimens
taken from patients were also recorded. Patients presented
with stage IV disease undergo a very different approach
for treatment from those at other stages, as such, these
patients were excluded from the present study.
Surgical treatment was either in the form of total mas-
tectomy or breast conserving surgery, and sentinel node
biopsy and/or axillary dissection. The choice of treatment
option was mainly determined by the staging of the dis-
ease, the surgeon’s recommendation and the patient’s
wishes. Breast reconstruction was carried out for mastec-
tomy patients if the patient so desired after full coun-
selling by the responsible surgeon.
Administration of adjuvant therapy, whether in the
form of radiotherapy, chemotherapy, hormonal therapy,
targeted therapy or a combination of these modalities
depended on staging, histological grading and tumour
characteristics of the resected tumour. The decision was
made after an expert panel review of the characteristics of
the breast carcinoma. 
All patients were followed up regularly in private clinics
at 3–6-month intervals. The median follow up period was
27 months.
To facilitate analysis of the relationship of age with
clinical features and outcome, patients were grouped into
three age groups: < 40 years old, 40–69 years old and ≥ 70
years old. Data analysis was carried out with the Statistical
Package for Social Sciences version 15 (SPSS Inc., Chicago,
IL, USA). Continuous variables were analyzed with
Student’s t test, whereas categorical variables were ana-
lyzed with the χ2 test. Differences between groups were
considered statistically significant when p was < 0.05.
From 2003 to 2008, 2,079 patients were included and
gave complete information for analysis. They were all
female patients and their age ranged from 24 to 91 years,
with a median age of 48 years. They were separated into
three groups according to their age: group I, < 40 years
old; group II, 41–69 years old; and group III, ≥ 70 years
old. Following this segregation, group I had 334 patients
(16.5%), group II had 1,538 patients (76.1%) and group III
had 148 patients (7.3%).
Among these patients, 14.5% had a positive family his-
tory of breast malignancies, and 12.0% had a history of
surgery for benign breast disease. There were no differ-
ences among the three groups of patients for either of
these characteristics.
Results
The most frequent mode of presentation among the whole
group of patients was accidental discovery of a breast lump
by the patient. This occurred in 1,473 patients (70.9%).
This was more often seen in patients aged < 40 years old
(Pearson’s χ2 test, p = 0.025).
For TNM staging of all patients, 640 (42.5%) had stage
I breast carcinoma, 698 (46.4%) had stage II disease, and
167 (11.1%) had stage III disease (Table 1). The tumour
size and number of lymph nodes detected at the time of
presentation were similar among the three different age
groups. Thus there was no difference in the stage of breast
carcinoma among the three age groups.
For establishing the preoperative diagnosis of cancer,
1,597 (76.8%) patients had complete triple assessment
before surgery. Mammography was performed on 1,851
patients (89.0%). There was no difference in the efficacy
in diagnosing breast cancer between the three age groups
(Pearson’s χ2 test, p = 0.09; Table 2). Ultrasound was car-
ried out for 1,674 patients (80.5%). It showed similar effi-
cacy in confirming the diagnosis between the three age
groups (Pearson’s χ2 test, p = 0.206). Fine needle aspiration
cytology was performed on 987 patients (47.5%) and the
false-negative rate was 4%. Core needle biopsy was carried
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out for 742 patients (35.7%) and the false-negative rate
was 0.5%.
Analysis of tumour grading showed that tumours
with high grade were more frequently seen in younger
patients (Pearson’s χ2 test, p = 0.000) and the incidence of
lymphovascular invasion was also higher (Pearson’s χ2
test, p = 0.011). For hormonal receptor status, the three
age groups showed a similar incidence of oestrogen and
progesterone receptor positivity, and Ki67 index, although
there were no significant differences. Young patients were
more likely to carry the cerb-B2 receptor (Pearson’s χ2 test,
p = 0.001).
For surgical treatment of all patients, older patients
were more likely to undergo mastectomy (Pearson’s χ2
test, p = 0.000), whereas younger patients more frequently
underwent breast conserving surgery (Pearson’s χ2 test,
p = 0.000). For those who underwent mastectomy, the
incidence of breast reconstruction was less in the older
patients (Pearson’s χ2 test, p = 0.000; Table 3). When the
choice of operation was analysed in relation to tumour
size, tumours smaller than 5 cm showed a positive corre-
lation between choice of operation (mastectomy vs. breast
conserving surgery) and age (Pearson’s χ2 test, tumour
size < 2 cm, p = 0.000; tumour size 2–5 cm, p = 0.001).
However, for tumours exceeding 5 cm, there was no 
difference between the three age groups and choice of
operation (Pearson’s χ2 test, p = 0.67).
Adjuvant treatment was given to 1,197 patients (57.6%).
This included chemotherapy, hormonal therapy, targeted
therapy, radiotherapy or a combination of these treat-
ment modalities (Table 4). For patients aged ≥ 70 years,
combination therapy was the most commonly used regi-
men, whereas, for patients ≥ 70 years old, single hormonal
therapy was used most frequently (Pearson’s χ2 test,
p < 0.0005).
For the whole group of patients, the 3-year disease-free
survival rate was 97.8% and there was no significant dif-
ference among the three age groups. The projected 5-year
survival was well over 90% (Log-rank test, p = 0.814)
(Figure 1).
Discussion
Age has been repeatedly identified as an important prog-
nostic factor in breast cancer.5,9 Young women diagnosed
with breast cancer have poorer overall survival and are
twice as likely to suffer recurrence when compared with
older patients with similar staging.10–13 Some authors
have even suggested that breast cancer in young patients
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Table 1. TNM staging (American Joint Committee on Cancer,
version 6) in the three age groups
Age groups (yr) < 40 40–69 ≥ 70
T stage
T1 147 (54.2%) 737 (60.0%) 56 (46.3%)
T2 114 (42.0%) 441 (35.9%) 59 (48.8%)
T3 8 (3.0%) 42 (3.4%) 4 (3.3%)
T4 2 (0.7%) 8 (0.7%) 2 (1.7%)
N stage
N0 116 (51.3%) 532 (52.9%) 43 (52.4%)
N1 76 (33.6%) 321 (31.9%) 26 (31.7%)
N2 21 (9.3%) 97 (9.8%) 8 (9.8%)
N3 13 (5.8%) 40 (5.4%) 5 (6.1%)
Overall stage
I 91 (40.6%) 504 (43.0%) 45 (40.2%)
II 133 (54.5%) 509 (43.4%) 56 (50.0%)
III 20 (8.2%) 136 (11.6%) 11 (9.8%)
Table 2. Imaging modalities performed
Age groups (yr) < 40 40–69 ≥ 70
Mammogram 300 1,421 130
Ultrasound 269 1,281 124
Fine needle aspiration 180 729 78
Core needle biopsy 97 588 57
Table 3. Types of surgery performed
Age groups (yr) < 40 (n= 334) 40–69 (n= 1538) ≥ 70 (n= 148)
Mastectomy 130 (39.0%) 752 (48.9%) 87 (58.8%)
Breast conservative therapy 185 (55.4%) 705 (45.8%) 45 (30.4%)
Breast reconstruction 76 (22.8%) 171 (11.1%) 0 (0%)
is an entirely different entity from that in elderly
patients.9,14,15 Some reports have suggested that breast
screening would be most effective if it could be targeted
at those in the 40–69 years age group.
We separated our patients into three age groups and
analyzed the various clinical factors in relation to these
groups, to see if there was a relationship between age and
clinical factors. The age ranges for the three groups were
chosen because those < 40 years are usually regarded 
as young, and chemotherapy usually does not show any
difference in survival for those ≥ 70 years as old.16,17
The patients who attended our clinic for management
were from the middle and upper social classes and repre-
sented the more affluent population in Hong Kong. They
were able to provide a reliable family history of breast cancer.
Among them, 14.5% had a family history of breast cancer
and there was no difference between the age groups. This
was similar to the study by Couto et al.18 The incidence of
previous breast surgery among 12% of patients was also
similar to other studies in the western literature.
Most patients in the present study presented to the
breast clinic with a mass in the breast, and 70.9% of the
whole group of patients detected the mass through self
examination. Most studies have postulated that breast
screening programmes should target patients aged 40–69
years old.3
The majority of our patients were ethnic Chinese. Their
clinical characteristics were markedly different from those
of the Caucasian population. Our median age at presenta-
tion was only 48 years, and this was similar to that in other
Asian countries such as China, Singapore, Taiwan, India
and also similar to Saudi Arabia, all of which were around
the mid-40s. This was much lower than the median age of
65 years reported in the western literature.2,16,19,20
At presentation, the majority of patients in our study
had early-stage disease with small tumours and some had
lymph node metastasis. Only 11% of the patients had stage
III disease. The distribution of disease stage was similar
among the three age groups. The incidence of advanced-
stage disease on presentation was lower than in other
Asian studies.16 This reflects that the present study was
focused on a selected group of affluent Chinese patients
in Hong Kong. Their relatively higher social status and
educational background enabled them to have a higher
awareness when they discovered a suspicious breast lump.
They were also more willing and available to commit
resources to medical check-ups and intervention. 
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Table 4. Types and incidence of different forms of adjuvant therapy administered 
Adjuvant treatment
Age (yr)
CT HT RT CT + HT CT + RT HT + RT CT + HT + RT
< 40 (n= 212)
Count (%) 7 (3.3) 18 (8.5) 31 (14.6) 19 (9.0) 34 (16.0) 30 (14.2) 73 (34.4)
40–69 (n= 923)
Count (%) 52 (5.6) 141 (15.3) 162 (17.6) 110 (11.9) 106 (11.5) 151 (16.4) 201 (21.8)
≥ 70 (n= 62)
Count (%) 2 (3.2) 22 (35.5) 20 (32.3) 0 (0) 1 (1.6) 15 (24.2) 2 (3.2)
Total
Count 61 181 213 129 141 196 276
CT = chemotherapy; HT = hormonal therapy; RT = radiotherapy.
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Figure 1. Disease-free survival for the three age groups.
Most patients either underwent a mammogram or an
ultrasound or both examinations performed on presenta-
tion. Fine needle aspiration or core needle biopsy was usu-
ally carried out at the discretion of the managing surgeon,
to confirm the malignancy. For all patients, the diagnosis
of breast carcinoma was made either through cytology or
histology before discussing with the patient the optimal
management strategy. In our patients, the overall incidence
of completing a triple diagnostic procedure was 76.8%,
which was comparable to the results of other studies.21
The planning of surgical treatment involved detailed
discussion with the patients in relation to their disease
stage. The surgical procedures with the best chance of
cure were offered to the patient. This included a similar
outcome for lumpectomy with adjuvant therapy com-
pared with mastectomy,22,23 and a negative impact on body
image perception and social behaviour following mastec-
tomy.24 Patients then selected the surgical procedure that
they considered to be most acceptable. 
For younger patients in the present study with tumour
mass less than 5 cm, breast conservative surgery rather
than mastectomy was more frequently carried out, and
the incidence of breast reconstruction was also signifi-
cantly higher. For patients who presented with larger
tumours > 5 cm, there was no difference in the extent 
of resection among the age groups, and mastectomy was
the operation of choice for cure.
Pathological study of the surgical specimens showed
that the histological grading was higher and the incidence
of lymphovascular permeation was significantly more fre-
quent in young patients. They were more likely to have the
c-erb B2 receptor, but the incidence of oestrogen receptor,
progesterone receptor and Ki67 index was similar among
the three groups. However, these did not affect the 
outcome because more aggressive treatment was given to
our younger patients, based on these worse prognostic
factors.
Adjuvant treatment in the form of chemotherapy, hor-
monal therapy, targeted therapy or radiotherapy, or a
combination of these treatment modalities was adminis-
tered to 1,197 patients (57.6%), depending on the status
of the tumour at the time of the operation and the patho-
logical findings. In general, for younger patients, a more
aggressive management strategy such as the combination
of two or three modes of therapy was frequently used,
whereas for older patients, single hormonal therapy was
used more often (p < 0.0005). 
The 3-year disease-free survival rate was 97.8% for the
whole group of 2,079 patients. Although the follow-up
period was relatively short, the survival plots of the three
groups nearly coincided with each other, and there was no
difference among the three age groups (Log-rank test
p = 0.56). 
Age is an important factor in management of breast
cancer. It has been postulated that breast cancer in young
patients has a different morphology than that in elderly
patients.14,16
A study from Saudi Arabia has shown that age < 40
years was an independent prognostic factor for disease-
free survival, in addition to nodal status, pathological
tumour size, staging, and hormonal receptor status.
Younger patients also had a higher likelihood of undergo-
ing chemotherapy when compared with elderly patients.16
Albain et al14 have also found that young age was an inde-
pendent predictor of adverse outcome, although less
important than other factors such as tumour grading.
This was also the finding of Love et al,25 who have studied
696 Vietnamese and Chinese women with breast cancer.
Conversely, Crowe et al26 have studied 1,353 patients and
reported that, although younger patients had more
aggressive and advanced breast cancer on presentation,
Cox regression showed that it was not a significant 
predictor for either disease-free or overall survival. 
It had been suggested previously17 that oestrogen recep-
tor positivity is more likely in elderly patients, thus pre-
scription of hormone receptor antagonists (tamoxifen)
without surgery has been suggested as another option of
management for elderly patients. In the present study,
although it was a selected patient population, our 3-year
disease-free survival rate for elderly patients aged ≥ 70
years following surgery was > 90%. Surgery has remained
an effective treatment for this group of patients.
The most common clinical presentation of breast can-
cer in this selected group of patients was self discovery of
a breast lump, and this was more common in younger age
groups, because of the absence of screening women before
the age of 40 years. Our study also showed that when the
primary tumour was small, younger patients had a higher
incidence of breast conserving surgery and reconstruction
after mastectomy. Mastectomy alone was more com-
monly carried out for elderly patients. Although breast
cancer in younger Chinese patients was more aggressive
histologically, with a higher incidence of lymphovascular
invasion, the differences between clinical presentation,
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tumour size, staging and survival were similar among dif-
ferent age groups. The management strategy should be
determined by the cancer staging and tumour character-
istics rather than by age.
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